Increased expression of CC chemokine ligand 18 in extrinsic atopic dermatitis patients

Chang Ook Park, Hee Jung Lee, JuHee Lee, Wen Hao Wu, Nam Soo Chang, Liu Hua, Mingeol Lee, Kwanghoon Lee

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background: Although most patients with atopic dermatitis (AD) show high total and allergen-specific serum immunoglobulin E (IgE) levels, a small subgroup of AD patients have normal total IgE levels and negative serum allergen-specific IgE. This subgroup has been termed 'intrinsic' AD (IAD) as a counterpart to 'extrinsic' AD (EAD). However, the difference of chemokines between IAD and EAD has not yet been evaluated. Objective: We investigated the expression of CC chemokine ligand (CCL) 17, CCL22, and CCL18 in patients with IAD and EAD, which are known to be highly expressed in AD patients. Methods: We assessed the protein levels of these chemokines in peripheral blood mononuclear cells (PBMCs), sera and lesional skins. We also evaluated CCL18 mRNA levels in monocytes, Langerhans cell (LC)-like dendritic cells (DCs) and inflammatory dendritic epidermal cell (IDEC)-like DCs from both types of AD patients. Results: There were no significant differences in CCL17 and CCL22 expression in PBMCs, sera and lesional skins of patients with IAD and EAD. CCL18 expression did not differ in PBMCs, sera and LC-like DCs from the two subgroups, but strong CCL18 expression was observed in lesional skins and IDEC-like DCs in patients with EAD. Lastly, serum CCL18 levels significantly decreased after immunotherapy. Conclusion: This study suggests that the chemokine micromilieu, especially the level of CCL18, is different between EAD and IAD patients. High Fc∈RI surface-expressing DCs, such as IDEC, were the major source of CCL18, and produced a prominent CCL18 microenvironment in EAD patients compared with IAD patients.

Original languageEnglish
Pages (from-to)24-29
Number of pages6
JournalExperimental Dermatology
Volume17
Issue number1
DOIs
Publication statusPublished - 2008 Jan 1

Fingerprint

CC Chemokines
Atopic Dermatitis
Ligands
Langerhans Cells
Chemokines
Dendritic Cells
Immunoglobulin E
Skin
Blood
Allergens
Serum
Blood Cells
Messenger RNA
Immunotherapy
Monocytes
Proteins

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Biology
  • Dermatology

Cite this

Park, Chang Ook ; Lee, Hee Jung ; Lee, JuHee ; Wu, Wen Hao ; Chang, Nam Soo ; Hua, Liu ; Lee, Mingeol ; Lee, Kwanghoon. / Increased expression of CC chemokine ligand 18 in extrinsic atopic dermatitis patients. In: Experimental Dermatology. 2008 ; Vol. 17, No. 1. pp. 24-29.
@article{54f160f50c3f43adaeea5cd45228fd20,
title = "Increased expression of CC chemokine ligand 18 in extrinsic atopic dermatitis patients",
abstract = "Background: Although most patients with atopic dermatitis (AD) show high total and allergen-specific serum immunoglobulin E (IgE) levels, a small subgroup of AD patients have normal total IgE levels and negative serum allergen-specific IgE. This subgroup has been termed 'intrinsic' AD (IAD) as a counterpart to 'extrinsic' AD (EAD). However, the difference of chemokines between IAD and EAD has not yet been evaluated. Objective: We investigated the expression of CC chemokine ligand (CCL) 17, CCL22, and CCL18 in patients with IAD and EAD, which are known to be highly expressed in AD patients. Methods: We assessed the protein levels of these chemokines in peripheral blood mononuclear cells (PBMCs), sera and lesional skins. We also evaluated CCL18 mRNA levels in monocytes, Langerhans cell (LC)-like dendritic cells (DCs) and inflammatory dendritic epidermal cell (IDEC)-like DCs from both types of AD patients. Results: There were no significant differences in CCL17 and CCL22 expression in PBMCs, sera and lesional skins of patients with IAD and EAD. CCL18 expression did not differ in PBMCs, sera and LC-like DCs from the two subgroups, but strong CCL18 expression was observed in lesional skins and IDEC-like DCs in patients with EAD. Lastly, serum CCL18 levels significantly decreased after immunotherapy. Conclusion: This study suggests that the chemokine micromilieu, especially the level of CCL18, is different between EAD and IAD patients. High Fc∈RI surface-expressing DCs, such as IDEC, were the major source of CCL18, and produced a prominent CCL18 microenvironment in EAD patients compared with IAD patients.",
author = "Park, {Chang Ook} and Lee, {Hee Jung} and JuHee Lee and Wu, {Wen Hao} and Chang, {Nam Soo} and Liu Hua and Mingeol Lee and Kwanghoon Lee",
year = "2008",
month = "1",
day = "1",
doi = "10.1111/j.1600-0625.2007.00634.x",
language = "English",
volume = "17",
pages = "24--29",
journal = "Experimental Dermatology",
issn = "0906-6705",
publisher = "Wiley-Blackwell",
number = "1",

}

Increased expression of CC chemokine ligand 18 in extrinsic atopic dermatitis patients. / Park, Chang Ook; Lee, Hee Jung; Lee, JuHee; Wu, Wen Hao; Chang, Nam Soo; Hua, Liu; Lee, Mingeol; Lee, Kwanghoon.

In: Experimental Dermatology, Vol. 17, No. 1, 01.01.2008, p. 24-29.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Increased expression of CC chemokine ligand 18 in extrinsic atopic dermatitis patients

AU - Park, Chang Ook

AU - Lee, Hee Jung

AU - Lee, JuHee

AU - Wu, Wen Hao

AU - Chang, Nam Soo

AU - Hua, Liu

AU - Lee, Mingeol

AU - Lee, Kwanghoon

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Background: Although most patients with atopic dermatitis (AD) show high total and allergen-specific serum immunoglobulin E (IgE) levels, a small subgroup of AD patients have normal total IgE levels and negative serum allergen-specific IgE. This subgroup has been termed 'intrinsic' AD (IAD) as a counterpart to 'extrinsic' AD (EAD). However, the difference of chemokines between IAD and EAD has not yet been evaluated. Objective: We investigated the expression of CC chemokine ligand (CCL) 17, CCL22, and CCL18 in patients with IAD and EAD, which are known to be highly expressed in AD patients. Methods: We assessed the protein levels of these chemokines in peripheral blood mononuclear cells (PBMCs), sera and lesional skins. We also evaluated CCL18 mRNA levels in monocytes, Langerhans cell (LC)-like dendritic cells (DCs) and inflammatory dendritic epidermal cell (IDEC)-like DCs from both types of AD patients. Results: There were no significant differences in CCL17 and CCL22 expression in PBMCs, sera and lesional skins of patients with IAD and EAD. CCL18 expression did not differ in PBMCs, sera and LC-like DCs from the two subgroups, but strong CCL18 expression was observed in lesional skins and IDEC-like DCs in patients with EAD. Lastly, serum CCL18 levels significantly decreased after immunotherapy. Conclusion: This study suggests that the chemokine micromilieu, especially the level of CCL18, is different between EAD and IAD patients. High Fc∈RI surface-expressing DCs, such as IDEC, were the major source of CCL18, and produced a prominent CCL18 microenvironment in EAD patients compared with IAD patients.

AB - Background: Although most patients with atopic dermatitis (AD) show high total and allergen-specific serum immunoglobulin E (IgE) levels, a small subgroup of AD patients have normal total IgE levels and negative serum allergen-specific IgE. This subgroup has been termed 'intrinsic' AD (IAD) as a counterpart to 'extrinsic' AD (EAD). However, the difference of chemokines between IAD and EAD has not yet been evaluated. Objective: We investigated the expression of CC chemokine ligand (CCL) 17, CCL22, and CCL18 in patients with IAD and EAD, which are known to be highly expressed in AD patients. Methods: We assessed the protein levels of these chemokines in peripheral blood mononuclear cells (PBMCs), sera and lesional skins. We also evaluated CCL18 mRNA levels in monocytes, Langerhans cell (LC)-like dendritic cells (DCs) and inflammatory dendritic epidermal cell (IDEC)-like DCs from both types of AD patients. Results: There were no significant differences in CCL17 and CCL22 expression in PBMCs, sera and lesional skins of patients with IAD and EAD. CCL18 expression did not differ in PBMCs, sera and LC-like DCs from the two subgroups, but strong CCL18 expression was observed in lesional skins and IDEC-like DCs in patients with EAD. Lastly, serum CCL18 levels significantly decreased after immunotherapy. Conclusion: This study suggests that the chemokine micromilieu, especially the level of CCL18, is different between EAD and IAD patients. High Fc∈RI surface-expressing DCs, such as IDEC, were the major source of CCL18, and produced a prominent CCL18 microenvironment in EAD patients compared with IAD patients.

UR - http://www.scopus.com/inward/record.url?scp=37249035577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37249035577&partnerID=8YFLogxK

U2 - 10.1111/j.1600-0625.2007.00634.x

DO - 10.1111/j.1600-0625.2007.00634.x

M3 - Article

VL - 17

SP - 24

EP - 29

JO - Experimental Dermatology

JF - Experimental Dermatology

SN - 0906-6705

IS - 1

ER -